Loe said interim tumor and
immunological response data are likely in FY H2 / 18 at the earliest.
Not exact matches
We expect that the CRI iAtlas will help to accelerate discovery and improve patient outcomes by providing researchers greater access to genomics
data to better understand the
immunological characteristics of the tumor microenvironment and its potential impact on patient
responses to immunotherapy,» said Jill O'Donnell - Tormey, Ph.D., CEO and director of scientific affairs at CRI.
Better understanding of these factors is a major area of interest in the lab, with some of the specific projects including tissue - specificity of cis - regulatory variants in the GTEx
data set, immune
response eQTLs where genetic variants contribute to inter-individual
response to
immunological stimuli, and haplotypic epistasis between regulatory and coding variants.